Registry Studying Advanced Imaging Scans for Advanced Prostate Cancer
Collects records on advanced scans used to check prostate cancer spread in men.
Key facts
- Who runs it
- Fundacio Puigvert
- Where
- Rotterdam, NetherlandsSee the siteAlso in 7 other countries, 22 sites
- Trial code
- Registry title
- European Registry of Next Generation Imaging in Advanced Prostate Cancer
- Status
- Recruiting
- People taking part
- 600 people, planned
- Started
- 17 Sept 2024
- Expected to end
- 23 Dec 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Imaging
- Record updated
- 11 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer confirmed by tissue testing. They need scans to check whether the cancer has spread, either at diagnosis or after it comes back.
- Age
- 18 years or older, with no upper age limit.
- Sex
- Men only.
- Disease stage
- Prostate cancer at the hormone-sensitive stage, at high risk of having spread. Scans are needed either at first diagnosis or when the cancer returns after local treatment.
Main reasons for not taking part
- Taking part in another study that requires next-generation imaging to check for spread
- Another significant illness that the investigator thinks makes joining a poor idea
- Not being able to complete the study
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult male patients (≥18 years with no upper age limit)
- Histologically proven prostate cancer
- Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment
- Patients who authorize their participation in the study by signing a written informed consent form (ICF)
Who cannot take part
- Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study
- Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment
- Patients who will not be able to complete the study
Where in Netherlands
Also in 7 other countries, 22 sites
- ERASMUS MC & Franciscus HospitalRotterdam, NetherlandsContact: Rodrick van der Bergh, MD, ProfNot yet recruiting
About the trial
What the trial wants to find out
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging.
Read full original descriptionShow less
Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form.
Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.
The 3 groups in the trial
- New generation imaging
Patients with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration either at the diagnostic workup of a "naïve" patient or at biochemical relapse/progression after local treatment with the use of next generation imaging ( whole-body MRI and PET/CT with new tracers (F/Ga-PSMA, 18F-fluciclovine)
Treatment: Imaging
- Conventional imaging
Patients with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration either at the diagnostic workup of a "naïve" patient or at biochemical relapse/progression after local treatment with the use of conventional imaging ( CT and bone scan)
Treatment: Imaging
- Conventional imaging and New generation imaging
Patients with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration either at the diagnostic workup of a "naïve" patient or at biochemical relapse/progression after local treatment with the use of conventional imaging ( CT and bone scan) AND next generation imaging
Treatment: Imaging
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- European Registry of Next Generation Imaging in Advanced Prostate Cancer
- Plain-language title
- Registry Studying Advanced Imaging Scans for Advanced Prostate CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 11 March 2025